Blood test may unlock targeted cancer drug for more patients
NCT ID NCT06129084
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a blood test can detect certain genetic changes (FGFR mutations) in patients with advanced bladder cancer better than the standard tissue biopsy. Currently, only patients with these mutations found in tumor tissue can get the drug erdafitinib. The blood test might catch mutations that tissue misses, potentially making more patients eligible for this targeted therapy. The study involves 260 participants and compares results from blood and tissue samples.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blood test (ctDNA testing for FGFR mutations)
What this could lead to
If successful, this blood test could identify more patients with bladder cancer who might benefit from the targeted drug erdafitinib, improving treatment access.
What could go wrong
This is a diagnostic study, not a treatment trial. The blood test may not prove more accurate than tissue testing, and even if it is, it does not guarantee better outcomes for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arthur J.E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
-
BC Cancer Agency
Vancouver, British Columbia, V5Z 4E6, Canada
-
CHU de Québec-Université Laval
Québec, Quebec, G1R 2J6, Canada
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
London Health Sciences Centre
London, Ontario, N6A 5W9, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada